 Use Code,Use,Therapeutic_Area,Use_Treatment_WRatio
U-1761 ,PLAQUE PSORIASIS,CARDIOLOGY/VASCULAR DISEASES (122) ,28
U-1796 ,TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1727 ,TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1068 ,TREATMENT OF ASTHMA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2001 ,USE FOR THE TREATMENT OF ASTHMA IN PATIENTS 6 YEARS OF AGE AND OLDER,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2002 ,USE FOR MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2122 ,USE FOR REDUCING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-636 ,TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1787 ,TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-949 ,HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-950 ,MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1507 ,TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1552 ,FOR HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1553 ,TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1384 ,METHOD OF TREATING MULTIPLE SCLEROSIS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2357 ,METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-839 ,TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2025 ,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-539 ,TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1873 ,ADMINISTRATION OF 25-HYDROXYVITAMIN D3 BY CONTROLLED RELEASE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2255 ,TREATING SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND THE SUSTAINED RELEASE IS OVER AT LEAST 10 HOURS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2256 ,"TREATING SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND CMAX IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2257 ,"TREATING SHPT IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE SERUM PARATHYROID HORMONE LEVEL AND CHANGE IN SERUM CONCENTRATION OF CALCIFEDIOL IN DOSE INTERVAL IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2258 ,"TREATING SECONDARY HYPERPARATHYROIDISM IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND CMAX24HR/C24HR IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2259 ,"TREATING SECONDARY HYPERPARATHYROIDISM IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND TMAX IS INCREASED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-219 ,TREATMENT OF PARKINSON'S DISEASE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1649 ,TREATMENT OF POST-ENCEPHALITIC PARKINSONISM,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2293 ,"USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-717 ,METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-739 ,METHOD FOR TREATING CONSTIPATION BY OPENING CIC CHANNELS IN A MAMMALIAN SUBJECT,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1203 ,METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1393 ,METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1394 ,METHOD FOR RELIEVING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING(I)24MICROG+/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1520 ,METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-874 ,METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1202 ,METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT  WITH IRRITABLE BOWEL SYNDROME,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1167 ,PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1502 ,PROPHYLAXIS OF PULMONARY EMBOLISM,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2030 ,PROPHYLAXIS OF VENOUS THROMBOSIS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2035 ,PROPHYLAXIS OF VENOUS THROMBOEMBOLISM,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2439 ,"TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2335 ,TREATMENT OF MELANOMA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2336 ,TREATMENT OF MELANOMA MEDIATED BY A B-RAF PROTEIN KINASE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2337 ,INDICATED IN COMBINATION WITH BINIMETINIB FOR THE TREATMENT OF MELANOMA WITH A BRAF MUTATION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2334 ,TREATMENT OF MELANOMA WITH A BRAF MUTATION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1571 ,TREATMENT OF GAUCHER DISEASE TYPE 1,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1617 ,METHOD OF TREATING MEDULLARY THYROID CANCER,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2413 ,FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-901 ,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1743 ,FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2447 ,TREATMENT OF SEVERE HYPERTRIGLYCERIDEMIA (500 MG/DL) IN ADULT PATIENTS AS AN ADJUNCT TO DIET,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1511 ,TREATMENT OF HYPERTRIGLYCERIDEMIA ,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1601 ,DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1602 ,METHOD OF ADMINISTERING PIRFENIDONE CAPSULES TO TREAT A FIBROTIC CONDITION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1603 ,METHOD FOR ADMINISTERING PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1608 ,DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF A FIBROSIS CONDITION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1669 ,"TREATMENT OF MULTIPLE MYELOMA, IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2371 ,THE TREATMENT OF FABRY PATIENTS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1086 ,TREATMENT OF AUTOIMMUNE DISEASE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2315 ,TREATMENT OF MULTIPLE SCLEROSIS IN THE PEDIATRIC PATIENT POPULATION WITH 0.25 MG FINGOLIMOD,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2149 ,TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1486 ,TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1998 ,"TREATING HR-POS., HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER WITH PALBOCICLIB IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE BASED THERAPY IN POSTMENOPAUSAL WOMEN OR FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1684 ,TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1946 ,TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2241 ,TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2242 ,TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1650 ,TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1456 ,TREATMENT OF MANTLE CELL LYMPHOMA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1947 ,TREATMENT OF MARGINAL ZONE LYMPHOMA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1491 ,TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2219 ,TREATMENT OF CHRONIC SMALL LYMPHOCYTIC LEUKEMIA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1683 ,TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1745 ,FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2150 ,TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2159 ,TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2228 ,TREATMENT OF SMALL LYMPHOCYTIC LEUKEMIA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1995 ,TREATMENT OF TARDIVE DYSKINESIA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1278 ,METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULTS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1516 ,METHOD OF TREATING CHRONIC IDIOPATHIC CONSTIPATION IN ADULT PATIENTS.,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1515 ,METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULT PATIENTS.,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1634 ,TREATMENT OF BRCA MUTATED OVARIAN CANCER USING PARP INHIBITOR,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1843 ,TREATMENT OF PSYCHOSIS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1844 ,TREATMENT OF PARKINSON'S DISEASE PSYCHOSIS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1845 ,TREATMENT OF PSYCHOSIS OR A SYMPTOM THEREOF,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1846 ,TREATMENT OF A NEURODEGENERATIVE DISEASE OR A SYMPTOM THEREOF,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1974 ,TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH PARKINSON'S DISEASE PSYCHOSIS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1722 ,TREATMENT OF BASAL CELL CARCINOMA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1677 ,TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (IPF),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1467 ,METHOD OF TREATING HEPATITIS C,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1360 ,USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2254 ,USE OF POMALIDOMIDE WITH DEXAMETHASONE FOR PATIENTS WITH MULTIPLE MYELOMA AFTER AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR AND DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETING THE LAST THERAPY,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1931 ,PROPHYLAXIS OR TREATMENT OF VENOUS AND ARTERIAL THROMBOTIC DISEASE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1759 ,METHOD OF REVERSING THE ANTICOAGULANT EFFECT OF DABIGATRAN USING IDARUCIZUMAB,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1982 ,USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1249 ,TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2007 ,"TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WHO ARE FLT3 MUTATION-POSITIVE, IN COMBINATION WITH STANDARD CYTARABINE AND DAUNORUBICIN INDUCTION AND CYTARABINE CONSOLIDATION CHEMOTHERAPY",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2171 ,ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RCC FOLLOWING NEPHRECTOMY,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-883 ,TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1406 ,TREATMENT OF MELANOMA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2296 ,"TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2298 ,"TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-836 ,A METHOD FOR THE TREATMENT OF LEUKEMIAS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1374 ,TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2474 ,METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION AFTER SURGICAL RESECTION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2469 ,METHOD OF TREATING CANCEROUS SOLID TUMORS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2470 ,METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2475 ,METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION IN A PEDIATRIC PATIENT,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2160 ,MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 5 MG OF MELOXICAM,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2165 ,MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 10 MG OF MELOXICAM,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-727 ,FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1034 ,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-842 ,INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1179 ,TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1588 ,THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC).,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2345 ,TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-88 ,TREATMENT OF MODERATE PLAQUE PSORIASIS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-742 ,TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1408 ,TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1858 ,TREATMENT OF PLAQUE PSORIASIS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-540 ,TREATMENT OF FUNGAL INFECTIONS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-805 ,TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2366 ,TREATMENT OF LIVER DISEASE THROUGH NUTRITION FOR PATIENTS UNDER THE AGE OF 12,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1741 ,PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1769 ,TREATEMENT OF PAIN BY TRANSMUCOSAL DELIVERY OF BUPRENORPHINE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1087 ,DETECTION OF NON-MUSCLE INVASIVE PAPILLARY CANCER OF THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2250 ,DETECTION OF CARCINOMA IN THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2310 ,FOR CLEANSING OF THE COLON IN PREPARATION FOR COLONOSCOPY IN ADULTS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-543 ,TREATMENT OF SCHIZOPHRENIA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1632 ,"TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1530 ,USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-493 ,TREATMENT OF TYPE 2 DIABETES MELLITUS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2139 ,TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-412 ,TREATMENT OF TYPE 2 DIABETES,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2363 ,ADMINISTRATION OF RISPERIDONE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1629 ,METHOD OF TREATING ACROMEGALY,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1434 ,TREATMENT OF PANCREATIC CANCER,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1092 ,TREATMENT OF BREAST CANCER,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1290 ,TREATMENT OF LUNG CANCER,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1117 ,TREATMENT OF BREAST CANCER,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1916 ,PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY (CINV),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2312 ,TREATMENT OF HYPERKALEMIA IN ADULTS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1226 ,A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2148 ,A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY MEASURING AND DISPLAYING AN INDICATION OF THE CALCULATED DELIVERY CONCENTRATION OF NITIRIC OXIDE AS COMPARED TO THE DESIRED DELIVERY CONCENTRATION OF NITRIC OXIDE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1033 ,TOPICAL TREATMENT OF ACNE VULGARIS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-804 ,TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1222 ,TO INHIBIT THE PROLIFERATIVE ACTIVITY OF NEOPLASTIC CELLS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1440 ,USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1311 ,METHOD OF TREATING CYSTIC FIBROSIS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2234 ,USE OF IVACAFTOR FOR TREATING CYSTIC FIBROSIS IN A PATIENT WITH A MILD TO MODERATE CF PHENOTYPE WITH AT LEAST ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2396 ,TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE DOSAGE UNIT COMPRISING LUMACAFTOR AS RECITED IN CLAIM 1 OF US PATENT 8716338 AND IVACAFTOR,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2397 ,TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE DOSAGE UNIT COMPRISING LUMACAFTOR AND IVACAFTOR AS RECITED IN CLAIM 1 OF US PATENT 9192606,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2376 ,TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS AND LESS THAN ABOUT 30% CRYSTALLINE IVACAFTOR,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1791 ,"EMERGENCY TREATMENT OF ADULT & PEDIATRIC PATIENTS FOLLOWING FLUOROURACIL OR CAPECITABINE OVERDOSE,OR WHO EXHIBIT EARLY-ONSET,SEVERE OR LIFE-THREATENING CARDIAC OR CNS TOXICITY OR UNUSUALLY SEVERE ADVERSE REACTIONS WITHIN 96 HOURS",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-708 ,TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1271 ,TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE(PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MORE ANTI-LEUKEMIA THERAPIES,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2091 ,"TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, IN A PATIENT NOT HOMOZYGOUS FOR THE UGT1A1*28 ALLELE",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1792 ,TREATMENT OF OTIC INFECTION OR INFLAMMATION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-764 ,TREATMENT OF SCHIZOPHRENIA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1826 ,"TREATMENT OF HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION WITH PALBOCICLIB IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2163 ,"TREATMENT OF HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER-2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION WITH PALBOCICLIB OR ABEMACICLIB IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1891 ,TREATMENT OR PREVENTION OF NAUSEA AND VOMITING,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2316 ,TREATMENT OF DYSPAREUNIA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2317 ,TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2003 ,"A METHOD OF POSITIONING AN INTRAUTERINE SYSTEM BY HOLDING AN INSERTER HANDLE WITH ONE HAND, ADVANCING THE INSERTER THROUGH THE CERVIX AND INTO THE UTERUS, AND RETRACTING A SLIDER ON THE HANDLE TO RELEASE THE INTRAUTERINE SYSTEM",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2348 ,A METHOD FOR PREVENTION OF PREGNANCY,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1816 ,TREATMENT OF A UREA CYCLE DISORDER,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1383 ,DOSAGE ADJUSTMENT OF A NITROGEN SCAVENGING DRUG IN THE TREATMENT OF A UREA CYCLE DISORDER,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1932 ,METHOD OF TREATING MILD TO MODERATE ATOPIC DERMATITIS.,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2267 ,METHOD FOR RELIEVING THE PAIN ASSOCIATED WITH POST-HERPETIC NEURALGIA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-645 ,TREATMENT OF ASTHMA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1401 ,"INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1691 ,INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2100 ,INDICATED FOR THE ONCE-DAILY TREATMENT OF ASTHMA IN PATIENTS 18 YEARS AND OLDER,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1424 ,"LONG-TERM, ONCE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1548 ,"FOR THE LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2125 ,THE TREATMENT OF AN INFLAMMATORY DISORDER OF THE RESPIRATORY TRACT BY ONCE-PER-DAY ADMINISTRATION OF A PHARMACEUTICAL FORMULATION COMPRISING FLUTICASONE FUROATE AND A LONG-ACTING BETA2 ADRENORECEPTOR AGONIST,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2128 ,"METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA INHALATION",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2129 ,"METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA TOPICAL APPLICATION",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1544 ,TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL).,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1517 ,TREATMENT OF BACTERIAL INFECTIONS USING A TWO-DOSE REGIMEN OF DALBAVANCIN.,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1715 ,P2Y12 PLATELET INHIBITOR FOR USE AS ADJUNCT TO PERCUTANEOUS CORONARY INTERVENTION TO REDUCE RISK OF VARIOUS DISEASES/CONDITIONS IN PATIENTS NOT TREATED WITH A P2Y12 PLATELET INHIBITOR AND NOT GIVEN A GLYCOPROTEIN IIB/IIIA INHIBITOR,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1926 ,"METHOD OF TREATING, REDUCING THE INCIDENCE OF, OR PREVENTING AN ISCHEMIC EVENT IN A PATIENT UNDERGOING PCI BY ADMINISTERING INTRAVENOUSLY 30 UG/KG BOLUS BEFORE PCI AND CONTINUOUS INFUSION OF 4 UG/KG/MIN FOR AT LEAST 2 HOURS OR THE DURATION OF THE PCI",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1260 ,TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2319 ,KYPROLIS IS INDICATED IN COMBINATION WITH DEXAMETHASONE OR WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2449 ,TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1569 ,TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1570 ,TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS USING A SINGLE DOSE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-282 ,METHOD OF TREATING BACTERIAL INFECTIONS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2341 ,METHOD OF RECONSTITUTING A LYOPHILIZED LIPOSOMAL COMPOSITION FOR ADMINISTERING CYTARABINE AND DAUNORUBICIN TO TREAT ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2342 ,METHOD OF ADMINISTERING A RECONSTITUTED LIPOSOMAL COMPOSITION CONTAINING CYTARABINE AND DAUNORUBICIN TO TREAT ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-36 ,METHODS OF TREATING BACTERIAL ILLNESSES,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1672 ,TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1673 ,"TREATMENT OF COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2460 ,"VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF CORONARY ARTERY BYPASS GRAFT IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2461 ,"VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF CARDIOVASCULAR BYPASS GRAFT AND VASCULATURE IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2462 ,"VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF VESSEL WITH ARTERIOVENOUS MALFORMATION IN VASCULAR,  GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2464 ,"VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF TRANSPLANTED ORGAN OR ATTACHED VESSEL IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2466 ,"VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF DONOR ORGAN OR ATTACHED VESSEL IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-257 ,TREATMENT OF HIV INFECTION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1766 ,TREATMENT OF HYPERKALEMIA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1576 ,TREATMENT OF LEUKEMIA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2489 ,TREATMENT OF MODERATE TO SEVERE OPIOID USE DISORDER,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2177 ,TREATING OPIOID ADDICTION BY SUBCUTANEOUS INJECTION OF BUPRENORPHINE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2179 ,IN SITU FORMATION OF SOLID BUPRENORPHINE COMPOSITION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2180 ,TREATING ADDICTION WITH 100 MG OR 300 MG DOSE OF BUPRENORPHINE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2207 ,TREATING ADDICTION BY SUBCUTANEOUS INJECTION OF BUPRENORPHINE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2208 ,TREATING ADDICTION BY ONCE PER MONTH ADMINISTRATION OF BUPRENORPHINE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2210 ,TREATING OPIOID ADDICTION BY 100 MG OR 300 MG DOSE BUPRENORPHINE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2211 ,TREATING OPIOID ADDICTION BY ADMINISTRATION OF BUPRENORPHINE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1419 ,TREATMENT OF ACUTE CYANIDE POISONING THAT IS JUDGED TO BE LIFE THREATENING,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2222 ,RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1680 ,TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1524 ,REDUCTION OF ELEVATED INTRAOCULAR PRESSURE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1900 ,TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1880 ,TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1578 ,TREATMENT OF ACUTE OTITIS MEDIA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2440 ,FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1942 ,TREATMENT OF SPINAL MUSCULAR ATROPHY BY INCREASING EXON-7 INCLUSION IN SMN2 MRNA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1943 ,TREATMENT OF SPINAL MUSCULAR ATROPHY,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1941 ,TREATMENT OF INFANTILE-ONSET SPINAL MUSCULAR ATROPHY,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2093 ,TREATMENT OF TYPE II SPINAL MUSCULAR ATROPHY,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2094 ,TREATMENT OF TYPE III SPINAL MUSCULAR ATROPHY,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-298 ,METHOD OF COMBATING BACTERIA IN A PATIENT,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1879 ,METHOD OF DIAGNOSING TUMORS USING POSITRON EMISSION TOMOGRAPHY,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1795 ,REVERSAL OF NEUROMUSCULAR BLOCKAGE INDUCED BY ROCURONIUM BROMIDE OR VECURONIUM BROMIDE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1794 ,REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2005 ,REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH GENERALIZED TONIC-CLONIC SEIZURES,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2006 ,"REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH MIXED SEIZURE PATTERNS THAT INCLUDE PARTIAL SEIZURES WITH COMPLEX SYMPTOMATOLOGY, GENERALIZED TONIC-CLONIC SEIZURES, OR OTHER PARTIAL OR GENERALIZED SEIZURES",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1239 ,MAGNETIC RESONANCE IMAGING OF THE LIVER,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1904 ,(I)TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY; (II)RESTORING/INCREASING FUNCTIONAL DYSTROPHIN PROTEIN; OR (III) INDUCING SKIPPING; EACH OF (I)-(III) IN PATIENTS HAVING A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1422 ,METHOD OF TREATING PATIENTS NEEDING AN IRON SUPPLEMENT,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2338 ,MAINTAINING MEAN ARTERIAL PRESSURE OF ABOUT 65 MMHG OR ABOVE WITH ABOUT 1 NG/KG/MIN TO ABOUT 40 NG/KG/MIN ANGIOTENSIN II IN HYPOTENSIVE PATIENTS TREATED WITH VASOPRESSIN OR A VASOPRESSIN ANALOGUE AND REDUCING VASOPRESSIN OR VASOPRESSIN ANALOGUE USE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1096 ,TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1812 ,TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-869 ,METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-116 ,METHOD OF MYOCARDIAL IMAGING,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-870 ,METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1003 ,A METHOD OF MYOCARDIAL PERFUSION IMAGING AND INCREASING CORONARY BLOOD FLOW,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1042 ,METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2262 ,MODIFIED DOSING REGIMEN FOR THE REDUCTION OF FEVER,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2378 ,TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2014 ,A METHOD OF TREATING SECONDARY HYPERPARATHYROIDISM (SHPT),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2013 ,TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1627 ,TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1565 ,"METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2328 ,METHOD OF USING PLAZOMICIN TO TREAT BACTERIAL INFECTIONS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1971 ,FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1972 ,FOR THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2479 ,METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2227 ,METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN GERIATRIC PATIENTS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1492 ,TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1529 ,ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2295 ,TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2427 ,USE FOR THE TREATMENT OF DROP SEIZURES IN PATIENTS WITH DRAVET SYNDROME,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2442 ,USE FOR THE TREATMENT OF ATONIC SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2443 ,USE FOR THE TREATMENT OF ATONIC SEIZURES IN PATIENTS WITH DRAVET SYNDROME,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2454 ,USE FOR THE TREATMENT OF DROP SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2425 ,USE FOR THE TREATMENT OF CONVULSIVE SEIZURES IN PATIENTS WITH DRAVET SYNDROME,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2426 ,USE FOR THE TREATMENT OF CONVULSIVE SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-735 ,METHOD OF TREATING CHRONIC IRON OVERLOAD,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1496 ,METHOD TO TREAT HEMANGIOMA.,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1988 ,METHOD TO TREAT INFANTILE HEMANGIOMA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-824 ,METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2140 ,METHOD OF TREATING PARTIAL ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2471 ,METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK FUSION GENE IN A PEDIATRIC PATIENT,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1101 ,METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1102 ,METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1353 ,"ADJUNCTIVE THERAPY TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LOW DENSITY LIPOPROTEIN-CHOLESTEROL, APOLIPOPROTEIN B, TOTAL CHOLESTEROL, AND NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN PTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2182 ,IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-831 ,METHOD OF ADMINISTERING LANREOTIDE ACETATE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2430 ,TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN AMYLOIDOSIS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1855 ,IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2009 ,METHOD OF TREATING POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE.,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-968 ,A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2313 ,"METHOD OF REDUCING THE RISK OF CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION, AND/OR NON-FATAL STROKE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE BY ADMINISTERING LIRAGLUTIDE",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2418 ,METHOD OF ADMINISTERING TESTOSTERONE ENANTHATE SUBCUTANEOUSLY,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2419 ,METHOD OF OPERATING AN INJECTION DEVICE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2205 ,TREATMENT OF SEBORRHEIC KERATOSES THAT ARE RAISED,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-281 ,"ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1951 ,TREATMENT OF ONYCHOMYCOSIS OF A TOENAIL,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-289 ,TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1703 ,TREATMENT OF RESPIRATORY COMPLAINTS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1547 ,"TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1430 ,"TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL AND PERENNIAL ALLERGIC RHINITIS",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-77 ,TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-81 ,RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-644 ,TREATMENT OF SEASONAL ALLERGIC RHINITIS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1667 ,"TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL ALLERGIC RHINITIS",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1876 ,METHOD OF ANESTHETIZING AT LEAST A PORTION OF THE MAXILLARY DENTAL ARCH,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1980 ,A METHOD OF TREATING NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2133 ,METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2402 ,TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2457 ,REINITIATION OF SCHIZOPHRENIA TREATMENT FOLLOWING A MISSED DOSE MORE THAN 9 MONTHS AGO,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2458 ,REINITIATION OF SCHIZOPHRENIA TREATMENT FOLLOWING A MISSED DOSE 4-9 MONTHS AGO,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1679 ,TREATMENT OF ACUTE OTITIS EXTERNA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2340 ,TREATMENT OF POSTOPERATIVE INFLAMMATION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1661 ,RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS ALSO TAKING LOW DOSE ASPIRIN,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1760 ,RISK-REDUCTION OF NSAID GASTRIC ULCER IN PATIENTS REQUIRING CHRONIC NSAID TREATMENT,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1781 ,RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS REQUIRING NSAID TREATMENT,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1827 ,A METHOD OF PROVIDING A SUBJECT WITH THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET ACCORDING TO CLAIM 1,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2203 ,A METHOD OF PROVIDING A SUBJECT WITH A THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET AS CLAIMED,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1752 ,PROPHYLAXIS OF ORGAN REJECTION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1247 ,MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1231 ,TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-494 ,TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2136 ,TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2137 ,TREATMENT OF POSTHERPETIC NEURALGIA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1475 ,USE OF ORENITRAM FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1).,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-860 ,"FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1364 ,MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1636 ,USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1638 ,TREATMENT OF HCV INFECTION USING PARITAPREVIR,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1687 ,TREATMENT OF HCV INFECTION USING OMBITASVIR,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1753 ,TREATMENT OF HCV INFECTION USING DASABUVIR,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-247 ,TREATMENT OF RHEUMATOID ARTHRITIS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2280 ,ADJUNCTIVE TREATMENT OF PATIENTS WITH TSC-ASSOCIATED PARTIAL-ONSET SEIZURES,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1749 ,ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1859 ,"TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1981 ,"IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER-2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2343 ,"TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HETEROZYGOUS FOR F508DEL AND A SECOND CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2399 ,"TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 12 YEARS AND OLDER, WITH A F508DEL OR G551D CFTR GENE MUTATION AND A A455E, 2789+5G->A, OR 3849+10KBC->T MUTATION, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF U.S PATENT 10058546",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2420 ,"TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 12 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,081,621",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2246 ,TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVING AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2247 ,TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF PATIENTS WITH A MILD TO MODERATE CLINICAL PHENOTYPE OF CYSTIC FIBROSIS HAVING AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2248 ,TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HETEROZYGOUS FOR THE F508DEL MUTATION AND A SECOND MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2275 ,"TREATING CYSTIC FIBROSIS PATIENTS AGES 12 AND OLDER, WHO ARE HOMOZYGOUS FOR F508DEL OR HAVE AT LEAST 1 CFTR GENE MUTATION RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS (<30% CRYSTALLINE) IVACAFTOR",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2318 ,"TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2041 ,TREATMENT OF PARTIAL-ONSET SEIZURES,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-620 ,TREATMENT OF INSOMNIA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1283 ,A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1171 ,REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1862 ,TREATMENT OF POST-MYOCARDIAL INFARCTION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1863 ,TREATMENT OF STROKE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1864 ,TREATMENT OF MYOCARDIAL INFARCTION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1865 ,TREATMENT OF THROMBOTIC STROKE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1866 ,TREATMENT OF STABLE AND UNSTABLE ANGINA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1867 ,METHOD OF INHIBITING PLATELET AGGREGATION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1868 ,"TREATMENT OF ARTERIAL THROMBOTIC COMPLICATIONS SELECTED FROM THE GROUP CONSISTING OF UNSTABLE ANGINA, THROMBOTIC OR EMBOLIC STROKE, TRANSIENT ISCHAEMIC ATTACKS, PERIPHERAL VASCULAR DISEASE AND MYOCARDIAL INFARCTION",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-185 ,METHOD OF TREATING HYPERTENSION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1480 ,TREATMENT OF ADVANCED RENAL CELL CARCINOMA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1220 ,TREATMENT OF RENAL CELL CARCINOMA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-56 ,AID TO SMOKING CESSATION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-614 ,TREATMENT OF SEXUAL DYSFUNCTION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1184 ,TREATMENT OF ERECTILE DYSFUNCTION AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-155 ,TREATMENT OF ERECTILE DYSFUNCTION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1776 ,METHOD OF USING COBIMETINIB FOR THE TREATMENT OF MELANOMA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-618 ,"USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB, NONHDL-C OR TG LEVELS; TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA; AND TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS.",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1724 ,METHOD OF INHIBITING HEPATITIS C VIRUS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-594 ,PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-904 ,TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1153 ,"IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, IS INDICATED FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN ANTIRETROVIRAL TREATMENT-NAIVE ADULT PATIENTS, AS SET FORTH IN THE LABELING, INCLUDING I&U; SECTION",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1723 ,TREATMENT OF HEART FAILURE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1470 ,FOR THE TREATMENT OF HEPATITIS C,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2237 ,"TREATMENT OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2270 ,"DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, THEN SUB-2400MG/DAY DOSE, THEN FULL DAILY DOSE IN TREATMENT OF IPF",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2073 ,"DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY ADMINISTERING FULL DAILY DOSE IN TREATMENT OF IPF",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2075 ,"DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS FOLLOWED BY ADMINISTERING 1602 MG/DAY IN TREATMENT OF IPF",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2083 ,"DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY 801 MG/DAY, DOSE, THEN 1602 MG/DAY IN TREATMENT OF IPF",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2056 ,"DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-1600 MG/DAY, FOLLOWING BY ADMINISTERING AT LEAST 1600 MG/DAY IN TREATMENT OF IPF",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2059 ,"DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, FOLLOWED BY FULL DAILY DOSE IN TREATMENT OF IPF",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2060 ,"DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, THEN AT LEAST 1600MG/DAY IN TREATMENT OF IPF",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2062 ,"DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-1600 MG/DAY DOSE, FOLLOWED BY ADMINISTERING AT LEAST 1600 MG/DAY DOSE IN TREATMENT OF IPF ",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2063 ,"DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY ADMINISTERING AT LEAST 1600 MG/DAY IN TREATMENT OF IPF",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2068 ,"DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, FOLLOWED BY FULL DAILY DOSE",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2069 ,"DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING A SUB-1600 MG/DAY DOSE, FOLLOWED BY ADMINISTERING AT LEAST 1602 MG/DAY",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2070 ,"DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, THEN SUB-1600 MG/DAY, THEN AT LEAST 1602 MG/DAY",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2044 ,"DOSE REDUCTION OF PIRFENIDONE BY ABOUT ONE HALF DURING CONCURRENT ADMINISTRATION OF CIPROFLOXACIN AT A DOSE OF 750 MG TWICE DAILY (1500 MG/DAY) TO REDUCE DRUG INTERACTIONS IN TREATMENT OF A FIBROTIC, INFLAMMATORY, OR AUTOIMMUNE DISORDER",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2078 ,"DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN LIMITS, THEN SUB-2400MG/DAY DOSE, THEN FULL DAILY DOSE IN TREATMENT OF IPF",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-106 ,TREATMENT OF EPILEPSY,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-649 ,A METHOD FOR TREATING A TUMOR DISEASE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1883 ,TREATMENT OF GASTROINTESTINAL STROMAL TUMORS (GIST),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2369 ,"FOR THE TREATMENT OF GENOTYPE 1, 4, 5 OR 6 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1701 ,A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1948 ,A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2243 ,TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-256 ,TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1016 ,"IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-EXPERIENCED ADULT PATIENTS, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO AN NNRTI AND OTHER ANTIRETROVIRAL AGENTS",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1237 ,"COMBO W/ OTHER ANTIRETROVIRALS FOR TX OF HIV-1 IN ANTIRETROVIRAL TX-EXPERIENCED PT 6 YEARS UP, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER  ANTIRETROVIRALS",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2354 ,COMBINATION WITH OTHER ANTIRETROVIRALS (ATV) FOR TREATMENT OF HIV-1 IN ATV TREATMENT-EXPERIENCED PATIENTS 2 YEARS AND OLDER WITH EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER ATV,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-900 ,INTEGRASE INHIBITION FOR THE TREATMENT OF HIV INFECTION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1201 ,FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1622 ,FOR THE TREATMENT OF POLYCYTHEMIA VERA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1573 ,USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2307 ,TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1337 ,METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1338 ,METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2355 ,"IN COMBINATION WITH AN AROMATASE INHIBITOR FOR THE TREATMENT OF PRE/PERIMENOPAUSAL OR POSTMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE-BASED THERAPY",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2356 ,"IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2166 ,TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2199 ,TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2201 ,TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN BIPOLAR DISORDER,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1754 ,FOR THE TREATMENT OF PULMONARY HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1751 ,"TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE BEEN PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY, AN ANTI-VEGF BIOLOGICAL THERAPY, AND IF RAS WILD-TYPE, AN ANTI-EGFR THERAPY",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2483 ,"TREATMENT OF HR-POSITIVE, HER-2 NEGATIVE, GBRCA-MUTATED METASTATIC BREAST CANCER, WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING, AND WITH ENDOCRINE THERAPY OR ARE INAPPROPRIATE FOR ENDOCRINE THERAPY",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2141 ,"TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1581 ,IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA.,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1582 ,TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2037 ,"MEKINIST IS INDICATED, AS A SINGLE AGENT OR IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2302 ,"MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS,  AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2305 ,"MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2331 ,INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2330 ,METHOD OF TREATING MELANOMA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2333 ,INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA WITH A BRAF MUTATION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1185 ,TREATMENT OF OPIOID-INDUCED CONSTIPATION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1459 ,TREATMENT OF CARCINOMA OF THE THYROID,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1696 ,TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2444 ,TREATMENT OF SUBJECTS HAVING BACTERIAL SKIN OR SKIN STRUCTURE INFECTION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1854 ,TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1445 ,"METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHERIN THE POLYSORBATE REPRESENTS 0.1 TO 1% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1820 ,"METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHEREIN THE POLYSORBATE REPRESENTS 0.1 TO 3% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2360 ,MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2411 ,"TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 12 YEARS OR OLDER WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE TABLET COMPRISING LUMACAFTOR AS RECITED IN CLAIM 1, 19, OR 21 OF U.S. PATENT NO. 10,076,513 AND IVACAFTOR",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1973 ,"METHOD OF TREATING CYSTIC FIBROSIS USING N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE AND 3-(6-(1-2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1911 ,METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS USING IVACAFTOR AND LUMACAFTOR,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2276 ,METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT AGE 6 OR OLDER HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS (LESS THAN ABOUT 30% CRYSTALLINE) IVACAFTOR,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1370 ,TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2403 ,TREATMENT OF PSORIASIS USING A DOSAGE TITRATION SCHEDULE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1504 ,USE OF OTEZLA (APREMILAST) FOR INHIBITING PDE4,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1505 ,USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1595 ,USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIASIS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1561 ,USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2232 ,TREATMENT OF PSORIATIC ARTHRITIS USING A DOSAGE TITRATION SCHEDULE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-3 ,TREATMENT OF HYPERTENSION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-930 ,TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2214 ,AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1098 ,METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2405 ,A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2406 ,A METHOD FOR TREATING A PATIENT 9 YEARS OF AGE AND OLDER SUFFERING FROM AN INFLAMMATORY SKIN DISORDER OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2407 ,A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2408 ,A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2409 ,"A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING SARECYCLINE HYDROCHLORIDE IN 60 MG, 100 MG OR 150 MG EQUIVALENT DOSES",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1321 ,TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-748 ,A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-780 ,A METHOD FOR THE TREATMENT OF CANCER,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-779 ,"A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1506 ,"TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST), INCLUDING BUT NOT LIMITED TO PATIENTS PREVIOUSLY TREATED WITH IMATINIB AND PATIENTS WITH GIST HAVING RESISTANCE TO A KIT TYROSINE KINASE INHIBITOR",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2353 ,TX OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENATES IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TX HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2365 ,TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INIBITS CYTOCHROME P450 MONOOXYGENASE IN ADULTS WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2351 ,TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 MUTATION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-867 ,TREATMENT OF MIGRAINE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1719 ,ACUTE TREATMENT OF MIGRAINE ,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1439 ,METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1668 ,METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1999 ,CHRONIC IDIOPATHIC CONSTIPATION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2230 ,IRRITABLE BOWEL SYNDROME WITH CONSTIPATION,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1429 ,TREATMENT OF PATIENTS WITH BREAST CANCER WHOSE TUMORS OVEREXPRESS THE HER2 RECEPTOR,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-999 ,TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2445 ,"TREATMENT IN COMBINATION WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2132 ,"IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2135 ,"AS MONOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY AND PRIOR CHEMOTHERAPY IN THE METASTATIC SETTING",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2251 ,"IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1709 ,TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1738 ,TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1301 ,TREATMENT OF DEEP VEIN THROMBOSIS (DVT),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1302 ,TREATMENT OF PULMONARY EMBOLISM (PE),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1200 ,REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1303 ,REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2142 ,REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE) IN PATIENTS AT CONTINUED RISK FOR RECURRENT DVT AND/OR AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1957 ,"PROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM IN PATIENTS UNDERGOING KNEE OR HIP REPLACEMENT SURGERY, WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2143 ,"AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS, TO REDUCE THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS AND/OR PULMONARY EMBOLISM IN CERTAIN PATIENTS WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1956 ,"FOLLOWING INITIAL 6 MONTHS TREATMENT FOR DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE), REDUCTION IN THE RISK OF RECURRENCE OF DVT AND OF PE WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2322 ,TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1707 ,TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF.,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1708 ,TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS.,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1481 ,REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1562 ,TREATMENT OF PATIENTS WITH HEPATIC ENCEPHALOPATHY (HE) ,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1994 ,REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) IN ADULTS ,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2456 ,TREATMENT OF ACUTE MYELOID LEUKEMIA (AML),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1813 ,TREATMENT OF PATIENTS INFECTED WITH HEPATITIS C VIRUS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1512 ,REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1801 ,REDUCTION OF SERUM URIC ACID LEVELS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1804 ,ACHIEVING A THERAPEUTIC BENEFIT IN A SUBJECT WITH GOUT,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1803 ,TREATMENT OF HYPERURICEMIA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1806 ,COADMINISTERING WITH ALLOPURINOL TO REDUCE SERUM URIC ACID (SUA) BELOW 4 MG/DL; BELOW 6MG/DL IN PATIENTS HAVING URIC ACID DEPOSITS; AND/OR BELOW 6MG/DL WITH SUA INTRADAY CHANGE MORE THAN 50% AND/OR ADVERSE EVENT RATE LESS THAN 15%,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1560 ,"A METHOD OF DISRUPTING LEUKOCYTE FUNCTION, INCLUDING AS AN INHIBITOR OF PI3KDELTA KINASE",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1549 ,FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1615 ,"FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1678 ,"FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1351 ,TREATMENT OF ACUTE PAIN,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2326 ,TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-326 ,METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1960 ,USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1064 ,TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1421 ,SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1841 ,"USE IN THE LONG-TERM, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1068 ,TREATMENT OF ASTHMA,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1787 ,TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1384 ,METHOD OF TREATING MULTIPLE SCLEROSIS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1385 ,METHOD OF TREATING AN AUTOIMMUNE DISEASE SELECTED FROM AUTOIMMUNE POLYARTHRITIS AND MULTIPLE SCLEROSIS BUT NOT TREATING PSORIATIC ARTHRITIS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-839 ,TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2459 ,"TREATMENT OF DYSKINESIA AND DECREASING OFF TIME IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2105 ,"TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING IMMEDIATE RELEASE LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2106 ,"TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2224 ,"TREATMENT OF DYSKINESIA AND INCREASING ON TIME WITHOUT TROUBLESOME DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1871 ,"TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH STAGE 3 OR 4 CHRONIC KIDNEY DISEASE USING CONTROLLED RELEASE, ORAL 25-HYDROXYVITAMIN D",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1872 ,USE OF SUSTAINED RELEASE 25-HYDROXYVITAMIN D IN TREATING PATIENTS HAVING 25-HYDROXYVITAMIN D INSUFFICIENCY OR DEFICIENCY,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1888 ,USE OF CONTROLLED RELEASE 25-HYDROXYVITAMIN D IN TREATING SECONDARY HYPERPARATHYROIDISM IN PATIENTS HAVING CHRONIC KIDNEY DISEASE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1920 ,USE OF EXTENDED RELEASE ORAL 25-HYDROXYVITAMIN D3 IN TREATING SECONDARY HYPERPARATHYROIDISM IN ADULT PATIENTS HAVING CHRONIC KIDNEY DISEASE STAGE 3 OR STAGE 4,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2255 ,TREATING SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND THE SUSTAINED RELEASE IS OVER AT LEAST 10 HOURS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2256 ,"TREATING SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND CMAX IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2257 ,"TREATING SHPT IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE SERUM PARATHYROID HORMONE LEVEL AND CHANGE IN SERUM CONCENTRATION OF CALCIFEDIOL IN DOSE INTERVAL IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2258 ,"TREATING SECONDARY HYPERPARATHYROIDISM IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND CMAX24HR/C24HR IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2259 ,"TREATING SECONDARY HYPERPARATHYROIDISM IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND TMAX IS INCREASED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2274 ,"MAINTAINING SERUM 25-HYDROXYVITAMIN D AT A LEVEL OF AT LEAST 30 NG/ML WITH ORAL, SUSTAINED RELEASE 25-HYDROXYVITAMIN D",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1645 ,"TREATMENT OF PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-219 ,TREATMENT OF PARKINSON'S DISEASE,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1646 ,"TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1649 ,TREATMENT OF POST-ENCEPHALITIC PARKINSONISM,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1508 ,"MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1556 ,"MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2293 ,"USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY",CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1214 ,METHOD FOR RELIEVING CONSTIPATION IN A HUMAN PATIENT THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MCG+/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1394 ,METHOD FOR RELIEVING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING(I)24MICROG+/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1345 ,USE IN RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH A DOSAGE UNIT COMPRISING 24MICROG+/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1395 ,USE IN RELIEVING OR PREVENTING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION WITH A DOSAGE UNIT COMPRISING 24MICROG +/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-873 ,METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME BY OPENING CHLORIDE CHANNELS (CIC),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1085 ,METHOD FOR TREATING IRRITABLE BOWEL SYNDROME AND METHOD FOR TREATING ABDOMINAL DISCOMFORT ASSOCIATED WITH IRRITABLE BOWEL SYNDROME,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1519 ,METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT WITH IRRITABLE BOWEL SYNDROME,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1167 ,PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT),CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-1502 ,PROPHYLAXIS OF PULMONARY EMBOLISM,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2030 ,PROPHYLAXIS OF VENOUS THROMBOSIS,CARDIOLOGY/VASCULAR DISEASES (122) ,86
U-2035 ,PROPHYLAXIS OF VENOUS THROMBOEMBOLISM,CARDIOLOGY/VASCULAR DISEASES (122) ,90
U-3 ,TREATMENT OF HYPERTENSION,CARDIOLOGY/VASCULAR DISEASES (122) ,90
U-3 ,TREATMENT OF HYPERTENSION,CARDIOLOGY/VASCULAR DISEASES (122) ,90
U-1512 ,REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS,CARDIOLOGY/VASCULAR DISEASES (122) ,90
U-1511 ,TREATMENT OF HYPERTRIGLYCERIDEMIA ,CARDIOLOGY/VASCULAR DISEASES (122) ,90
U-1171 ,REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME,CARDIOLOGY/VASCULAR DISEASES (122) ,92
U-805 ,TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES,DERMATOLOGY (109) ,95
U-727 ,FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),FAMILY MEDICINE (624) ,95
U-1743 ,FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY,GASTROENTEROLOGY (105) ,95
U-2242 ,TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION,HEMATOLOGY (135) ,95
U-1683 ,TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION,HEMATOLOGY (135) ,95
U-1680 ,TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS,IMMUNOLOGY (216) ,95
U-805 ,TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES,IMMUNOLOGY (216) ,95
U-1974 ,TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH PARKINSON'S DISEASE PSYCHOSIS,NEUROLOGY (189) ,95
U-727 ,FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),NEUROLOGY (189) ,95
U-2360 ,MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS,OBSTETRICS/GYNECOLOGY (WOMEN’S HEALTH) (120) ,95
U-2242 ,TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION,ONCOLOGY (263) ,95
U-1683 ,TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION,ONCOLOGY (263) ,95
U-1743 ,FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY,ONCOLOGY (263) ,95
U-1680 ,TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS,OPHTHALMOLOGY (56) ,95
U-805 ,TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES,PEDIATRICS/NEONATOLOGY (124) ,95
U-727 ,FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),PEDIATRICS/NEONATOLOGY (124) ,95
U-1974 ,TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH PARKINSON'S DISEASE PSYCHOSIS,PSYCHIATRY/PSYCHOLOGY (73) ,95
U-727 ,FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),PSYCHIATRY/PSYCHOLOGY (73) ,95
